FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382811312> ?p ?o ?g. }

• W4382811312 endingPage "S13" @default.
• W4382811312 startingPage "S12" @default.
• W4382811312 abstract "Neurotrophic tyrosine receptor kinase ( NTRK ) gene fusions are oncogenic drivers in various tumour types. Larotrectinib is a first-in-class, highly selective, central nervous system-active TRK inhibitor. Larotrectinib is approved for tumour-agnostic use in adult and paediatric patients with TRK fusion cancer, based on a rapid, robust and durable objective response rate (ORR) in various cancers. We report data on a subset of patients with TRK fusion GI cancer treated with larotrectinib with longer follow-up. Patients with TRK fusion GI cancer enrolled in the phase II larotrectinib clinical trial NAVIGATE (NCT02576431) were included. Responses were assessed per independent review committee (IRC) using RECIST v1.1. As of July 2022, 42 patients with TRK fusion GI cancer were enrolled. Median age was 67.0 years (range 32–90). The tumour types included were almost exclusively adenocarcinoma, including colorectal (CRC; n=24; 57%), pancreatic (n=7; 17%), cholangiocarcinoma (n=4; 10%), gastric (n=3; 7%), appendiceal (n=1; 2%) and duodenal (n=1; 2%) as well as hepatocarcinoma (n=1; 2%) and oesophageal squamous cell carcinoma (n=1; 2%). Among the patients with CRC, 14 were microsatellite-instability-high (MSI-H), eight were not MSI-H (including microsatellite stable) and two were microsatellite unknown. Overall, five (12%), 11 (26%), 15 (36%) and 11 (26%) patients had received 0, 1, 2 or ≥3 prior lines of systemic therapy, respectively. Among 34 patients eligible for IRC assessment (excludes eight patients who were on treatment for ≤4 months), ORR was 29% (95% CI 15–47): two complete responses (CR; 6%), eight partial responses (PR; 24%), 17 stable disease (SD; 50%), two progressive disease (6%) and five not evaluable (15%). Median time to response was 1.8 months. Median duration of response (DoR), progression-free survival (PFS) and overall survival (OS) was 27.3 months (95% CI 5.6–not estimable [NE]), 7.2 months (95% CI 3.5–12.3) and 14.1 months (95% CI 6.1–36.5); median follow-ups were 7.5, 11.1 and 13.3 months, respectively. In the 19 patients with CRC eligible for IRC assessment, ORR was 47% (95% CI 24–71): two CR (11%), seven PR (37%), nine SD (47%) and one not evaluable (5%). Of the nine responders, five were MSI-H. Median DoR, PFS and OS for all IRC-eligible patients with CRC was 27.3 months (95% CI 5.6–NE), 29.4 months (95% CI 5.4–NE) and 29.4 months (95% CI 6.1–NE); median follow-ups were 7.5, 10.7 and 13.9 months, respectively. Treatment duration for all GI patients ranged from 0.3 to 44+ months. At data cut-off, 23 patients were alive. Treatment-related adverse events (TRAEs) were predominantly Grade 1/2. Grade 3/4 TRAEs occurred in seven (17%) patients (two increased transaminases; one each abnormal hepatic function, anaemia, hyperaesthesia, leukopenia, nausea, neutropenia and thrombopenia). No patients discontinued treatment due to TRAEs. With longer follow-up, larotrectinib continued to demonstrate long-lasting responses, extended survival and a favourable safety profile in patients with TRK fusion GI cancer, particularly in those with MSI-H CRC. These results support the wider adoption of next-generation sequencing panels, which include NTRK gene fusions, in patients with GI cancer." @default.
• W4382811312 created "2023-07-02" @default.
• W4382811312 creator A5006640516 @default.
• W4382811312 creator A5007810585 @default.
• W4382811312 creator A5026095888 @default.
• W4382811312 creator A5030200922 @default.
• W4382811312 creator A5030650037 @default.
• W4382811312 creator A5040257073 @default.
• W4382811312 creator A5060949051 @default.
• W4382811312 creator A5063199354 @default.
• W4382811312 creator A5068715356 @default.
• W4382811312 creator A5072757135 @default.
• W4382811312 creator A5078552110 @default.
• W4382811312 date "2023-06-01" @default.
• W4382811312 modified "2023-09-25" @default.
• W4382811312 title "PD-28 Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis" @default.
• W4382811312 doi "https://doi.org/10.1016/j.annonc.2023.04.055" @default.
• W4382811312 hasPublicationYear "2023" @default.
• W4382811312 type Work @default.
• W4382811312 citedByCount "0" @default.
• W4382811312 crossrefType "journal-article" @default.
• W4382811312 hasAuthorship W4382811312A5006640516 @default.
• W4382811312 hasAuthorship W4382811312A5007810585 @default.
• W4382811312 hasAuthorship W4382811312A5026095888 @default.
• W4382811312 hasAuthorship W4382811312A5030200922 @default.
• W4382811312 hasAuthorship W4382811312A5030650037 @default.
• W4382811312 hasAuthorship W4382811312A5040257073 @default.
• W4382811312 hasAuthorship W4382811312A5060949051 @default.
• W4382811312 hasAuthorship W4382811312A5063199354 @default.
• W4382811312 hasAuthorship W4382811312A5068715356 @default.
• W4382811312 hasAuthorship W4382811312A5072757135 @default.
• W4382811312 hasAuthorship W4382811312A5078552110 @default.
• W4382811312 hasBestOaLocation W43828113121 @default.
• W4382811312 hasConcept C101544691 @default.
• W4382811312 hasConcept C104317684 @default.
• W4382811312 hasConcept C121608353 @default.
• W4382811312 hasConcept C126322002 @default.
• W4382811312 hasConcept C134139212 @default.
• W4382811312 hasConcept C143998085 @default.
• W4382811312 hasConcept C170493617 @default.
• W4382811312 hasConcept C171034665 @default.
• W4382811312 hasConcept C180754005 @default.
• W4382811312 hasConcept C185592680 @default.
• W4382811312 hasConcept C2779767149 @default.
• W4382811312 hasConcept C526805850 @default.
• W4382811312 hasConcept C55493867 @default.
• W4382811312 hasConcept C61320498 @default.
• W4382811312 hasConcept C71924100 @default.
• W4382811312 hasConcept C90924648 @default.
• W4382811312 hasConcept C92020748 @default.
• W4382811312 hasConceptScore W4382811312C101544691 @default.
• W4382811312 hasConceptScore W4382811312C104317684 @default.
• W4382811312 hasConceptScore W4382811312C121608353 @default.
• W4382811312 hasConceptScore W4382811312C126322002 @default.
• W4382811312 hasConceptScore W4382811312C134139212 @default.
• W4382811312 hasConceptScore W4382811312C143998085 @default.
• W4382811312 hasConceptScore W4382811312C170493617 @default.
• W4382811312 hasConceptScore W4382811312C171034665 @default.
• W4382811312 hasConceptScore W4382811312C180754005 @default.
• W4382811312 hasConceptScore W4382811312C185592680 @default.
• W4382811312 hasConceptScore W4382811312C2779767149 @default.
• W4382811312 hasConceptScore W4382811312C526805850 @default.
• W4382811312 hasConceptScore W4382811312C55493867 @default.
• W4382811312 hasConceptScore W4382811312C61320498 @default.
• W4382811312 hasConceptScore W4382811312C71924100 @default.
• W4382811312 hasConceptScore W4382811312C90924648 @default.
• W4382811312 hasConceptScore W4382811312C92020748 @default.
• W4382811312 hasLocation W43828113121 @default.
• W4382811312 hasOpenAccess W4382811312 @default.
• W4382811312 hasPrimaryLocation W43828113121 @default.
• W4382811312 hasRelatedWork W1973675534 @default.
• W4382811312 hasRelatedWork W1990390456 @default.
• W4382811312 hasRelatedWork W2018630641 @default.
• W4382811312 hasRelatedWork W2128901332 @default.
• W4382811312 hasRelatedWork W2391590910 @default.
• W4382811312 hasRelatedWork W2911032670 @default.
• W4382811312 hasRelatedWork W2922439869 @default.
• W4382811312 hasRelatedWork W2990849561 @default.
• W4382811312 hasRelatedWork W3026620415 @default.
• W4382811312 hasRelatedWork W4281671535 @default.
• W4382811312 hasVolume "34" @default.
• W4382811312 isParatext "false" @default.
• W4382811312 isRetracted "false" @default.
• W4382811312 workType "article" @default.